
    
      Trial design

      Phase II, multi-center, randomized, double-blind, placebo-controlled, parallel group study to
      evaluate the clinical efficacy and safety of alfuzosin (10mg, qd) from baseline to 8 weeks of
      treatment in female patients with non-neurogenic voiding dysfunction.

      Efficacy Assessment

        1. Primary efficacy endpoint

           Actual change in the score of IPSS from baseline to 8 weeks of treatment.

        2. Secondary efficacy endpoint

             -  IPSS parameters

             -  Percent change in the score of IPSS from baseline to 4 and 8 weeks of treatment.

             -  Actual and percent changes in the sub-scale of IPSS from baseline to 4 and 8 weeks
                of treatment

             -  Storage score: sum of questions 2, 4 and 7

             -  Voiding score: sum of questions 1, 3, 5 and 6

             -  Scored form of the Bristol Female Lower Urinary Tract Symptoms
                (BFLUTS-SF)parameters

             -  Actual and Percent change in BFLUTS-SF from baseline to 4 and 8 weeks of treatment.

             -  Actual and percent changes in the sub-scale of BFLUTS-SF from baseline to 4 and 8
                weeks of treatment

                  -  BFLUTS-FS: sum scores F1-F4

                  -  BFLUTS-VS: sum scores V1-V3

                  -  BFLUTS-IS: sum scores I1-I5

                  -  BFLUTS-sex: sum scores S1 & S2

             -  Uroflowmetry & PVR parameters

                  -  Numeric and percent changes from baseline to 4 and 8 weeks of treatment.

                  -  Maximum flow rate (mL/s)

                  -  Average flow rate (mL/s)

                  -  Post-void residual urine (mL)

                  -  Micturition diary parameters

                  -  Change in mean number of micturitions per 24 hours at weeks 4 and 8 relative
                     to baseline

                  -  Percent change of micturitions per 24 hours at weeks 4 and 8 relative to
                     baseline

                  -  Change in mean number of nighttime micturitions per 24 hours at weeks 4 and 8
                     relative to baseline

                  -  Percent change of nighttime micturitions per 24 hours at weeks 4 and 8
                     relative to baseline

                  -  Change in mean number of urgency episodes per 24 hours at weeks 4 and 8
                     relative to baseline (Urgency episodes are defined as those with Bladder
                     Sensation Scale rating of â‰¥ 3 in the diary).

                  -  Percent change of urgency episodes per 24 hours at weeks 4 and 8 relative to
                     baseline

                  -  Change in the mean and sum rating on the Bladder Sensation Scale at weeks 4
                     and 8 relative to baseline

                  -  Quality of life (QoL) parameters

                  -  Change in Bother score of IPSS from baseline to 4 and 8 weeks of treatment.

                  -  Change in QOL subscale scores of BFLUTS SF from baseline to 4 and 8 weeks of
                     treatment

                  -  BFLUTS-QoL: Sum scores QoL1-QoL5

                  -  Patient Perception of Bladder Condition (PPBC)

                  -  Change from baseline in PPBC after 8 weeks of double-blind treatment

                  -  Benefit, Satisfaction, and Willingness to Continue (BSW) Questions

                  -  Patient Perception of Treatment Benefit at week 8

                  -  Patient Perception of Treatment Satisfaction at week 8

                  -  Willingness to continue with treatment at week 8
    
  